Antiepileptic drug interactions in the elderly

Antiepileptic Drugs: Combination Therapy and Interactions

Volumn , Issue , 2005, Pages 273-293

  Conway, Jeannine M ^a,b   Cloyd, James C ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33750829039     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511545023.017     Document Type: Chapter

References (118)

1. Actos (2002). Package Insert. Takeda Pharmaceuticals America, Inc. Adebayo GI. Interaction between phenytoin and theophylline in healthy volunteers. Clin Exp Pharmacol Physiol 1988; 15(11): 883–887.
2. Algozzine GJ, Stewart RB, Springer PK. Decreased clearance of phenytoin with cimetidine. Ann Intern Med 1981; 95(2): 244–245.
3. Allen S. Cerebellar dysfunction following dextropropoxyphene-induced carbamazepine toxicity. Postgrad Med J 1994; 70(828): 764.
4. Aricept (2002). Package Insert. Eisai Co, Ltd. Bahls FH, Ozuna J, Ritchie DE. Interactions between calcium channel blockers and the anticonvulsants carbamazepine and phenytoin. Neurology 1991; 41(5): 740–742.
5. Baldwin SJ, Clarke SE, Chenery RJ. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 1999; 48(3): 424–432.
6. Bartle WR, Walker SE, Shapero T. Dose-dependent effect of cimetidine on phenytoin kinetics. Clin Pharmacol Ther 1983; 33(5): 649–655.
7. Beattie B, Biller J, Mehlhous B, et al. Verapamil-induced carbamazepine neurotoxicity. A report of two cases. Eur Neurol 1988; 28(2): 104–105.
8. Beers MH, Fingold SF, Ouslander JG, et al. Characteristics and quality of prescribing by doctors practicing in nursing homes. J Am Geriatr Soc 1993; 41(8): 802–807.
9. Benedetti MS. Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam Clin Pharmacol 2000; 14(4): 301–319.
10. Bergendal L, Friberg A, Schaffrath AM, et al. The clinical relevance of the interaction between carbamazepine and dextropropoxyphene in elderly patients in Gothenburg, Sweden. Eur J Clin Pharmacol 1997; 53(3–4): 203–206.
11. Bextra (2002). Package Insert. Pfizer. Birnbaum A, Hardie NA, Leppik IE, et al. Variability of total phenytoin serum concentrations within elderly nursing home residents. Neurology 2003; 60: 555–559.
12. Cacek AT. Review of alterations in oral phenytoin bioavailability associated with formulation, antacids, and food. Ther Drug Monit 1986; 8(2): 166–171.
13. Carter BL, Garnett WR, Pellock JM, et al. Effect of antacids on phenytoin bioavailability. Ther Drug Monit 1981; 3(4): 333–340.
14. Clarke TA, Waskell LA. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab Dispos 2003; 31(1): 53–59.
15. Clarke WR, Horn JR, Kawabori I, et al. Potentially serious drug interactions secondary to highdose diltiazem used in the treatment of pulmonary hypertension. Pharmacotherapy 1993; 13(4): 402–405.
16. Cloyd J, Conway J. Age-related changes in pharmacokinetics, drug interactions, and adverse effects. In Clinical Neurology of the Older Adult. J. Sirven, B. Malamut, eds. Philadelphia, PA: Lippincott Williams & Wilkins, 2002: 29–44.
17. Coulam CB, Annegers JF. Do anticonvulsants reduce the efficacy of oral contraceptives? Epilepsia 1979; 20(5): 519–525.
18. Denbow CE, Fraser HS. Clinically significant hemorrhage due to warfarin–carbamazepine interaction. South Med J 1990; 83(8): 981.
19. Depakote (2002). Package Insert. Abbott Laboratories. Depot M, Powell JR, Messenheimer JA, et al. Kinetic effects of multiple oral doses of acetaminophen on a single oral dose of lamotrigine. Clin Pharmacol Ther 1990; 48(4): 346–355.
20. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 2001; 40(7): 509–522.
21. Donahue S, Flockhart DA, Abernethy DR, et al. Ticlopidine inhibits phenytoin clearance. Clin Pharmacol Ther 1999; 66(6): 563–568.
22. Duragesic (2001). Package Insert. Janssen. Edwards RJ, Price RJ, Walts PS, et al. Induction of cytochrome P450 enzymes in cultured precision-cut human liver slices. Drug Metab Dispos 2003; 31(3): 282–288.
23. Eimer M, Carter BL. Elevated serum carbamazepine concentrations following diltiazem initiation. Drug Intell Clin Pharm 1987; 21(4): 340–342.
24. Facciola G, Avenoso A, Spina E, et al. Inducing effect of phenobarbital on clozapine metabolism in patients with chronic schizophrenia. Ther Drug Monit 1998; 20(6): 628–630.
25. Fattore C, Cipolla G, Gatti G, et al. Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia 1999; 40(6): 783–787.
26. Fitzgerald BJ, Okos AJ. Elevation of carbamazepine-10, 11-epoxide by quetiapine. Pharmacotherapy 2002; 22(11): 1500–1503.
27. Frigo GM, Lecchini S, Caranaggi M, et al. Reduction of phenytoin clearance caused by cimetidine. Eur J Clin Pharmacol 1983; 25(1): 135–137.
28. Fritze J, Unsorg B, Lanczik M, et al. Interaction between carbamazepine and fluvoxamine. Acta Psychiatr Scand 1991; 84(6): 583–584.
29. Furuta S, Kamada E, Suzuki T, et al. Inhibition of drug metabolism in human liver microsomes by nizatidine, cimetidine and omeprazole. Xenobiotica 2001; 31(1): 1–10.
30. Garrard J, Cloyd J, Gross C, et al. Factors associated with antiepileptic drug use among elderly nursing home residents. J Gerontol A Biol Sci Med Sci 2000; 55(7): M384–M392.
31. Garrard J, Harms S, Hardie N, et al. Antiepileptic drug use in nursing home admissions. Annals of Neurology 2003; 54: 75–85.
32. Gerbal-Chaloin S, Pascussi JM, Pichard-Garcia L, et al. Induction of CYP2C genes in human hepatocytes in primary culture. Drug Metab Dispos 2001; 29(3): 242–251.
33. Glue P, Banfield CR, Perhach JL, et al. Pharmacokinetic interactions with felbamate. In vitro–in vivo correlation. Clin Pharmacokinet 1997; 33(3): 214–224.
34. Goulden KJ, Dooley JM, Camfield PR, et al. Clinical valproate toxicity induced by acetylsalicylic acid. Neurology 1987; 37(8): 1392–1394.
35. Grimsley SR, Jann MW, Carter JG, et al. Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther 1991; 50(1): 10–15.
36. Guay D, Artz M, Hanlon J, et al. The pharmacology of aging. In Brocklehurst’s Textbook of Geriatric Medicine. R. Tallis, H. Fillit, eds. London, UK: Churchill Livingstone, 2003: 155–161.
37. Hansen BS, Dam M, Brandt J, et al. Influence of dextropropoxyphene on steady state serum levels and protein binding of three anti-epileptic drugs in man. Acta Neurol Scand 1980; 61(6): 357–367.
38. Haselberger MB, Freedman LS, Tolbert S. Elevated serum phenytoin concentrations associated with coadministration of sertraline. J Clin Psychopharmacol 1997; 17(2): 107–109.
39. Hauser W. Epidemiology of seizures in the elderly. In Seizures and Epilepsy in the Elderly. A. Rowan, R. Ramsay, eds. Boston, MA: Butterworth-Heinemann, 1997: 7–20.
40. Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug–drug interactions: an update. Curr Drug Metab 2002; 3(1): 13–37.
41. Hesslinger B, Normann C, Langosch JM, et al. Effects of carbamazepine and valproate on haloperidol plasma levels and on psychopathologic outcome in schizophrenic patients. J Clin Psychopharmacol 1999; 19(4): 310–315.
42. Hetzel DJ, Bochner F, Hallike JF, et al. Cimetidine interaction with phenytoin. Br Med J (Clin Res Ed) 1981; 282(6275): 1512.
43. Hoffman C, Rice D, Jung HY. Persons with chronic conditions. Their prevalence and costs. J Am Med Assoc 1996; 276(18): 1473–1479.
44. Jalil P. Toxic reaction following the combined administration of fluoxetine and phenytoin: two case reports. J Neurol Neurosurg Psychiatry 1992; 55(5): 412–413.
45. Jann MW, Ereshefsky L, Jaklod SR, et al. Effects of carbamazepine on plasma haloperidol levels. J Clin Psychopharmacol 1985; 5(2): 106–109.
46. Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997; 73(1): 67–74.
47. Kaufman KR, Gerner R. Lamotrigine toxicity secondary to sertraline. Seizure 1998; 7(2): 163–165.
48. Kendall AG, Boivin M. Warfarin-carbamazepine interaction. Ann Intern Med 1981; 94(2): 280.
49. Kidd RS, Straughn AB, Mayer MC, et al. Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele. Pharmacogenetics 1999; 9(1): 71–80.
50. Kirchheiner J, Bauer S, Meineke I, et al. Impact of CYP2C9 and CYP2C19 polymorphisms on tolbutamide kinetics and the insulin and glucose response in healthy volunteers. Pharmacogenetics 2002; 12(2): 101–109.
51. Klaassen SL. Ticlopidine-induced phenytoin toxicity. Ann Pharmacother 1998; 32(12): 1295–1298.
52. Kubacka RT, Ferrante JA. Carbamazepine–propoxyphene interaction. Clin Pharm 1983; 2(2): 104.
53. Labroo RB, Paine MF, Thummel KE, et al. Fentanyl metabolism by human hepatic and intestinal cytochrome P450 3A4: implications for interindividual variability in disposition, efficacy, and drug interactions. Drug Metab Dispos 1997; 25(9): 1072–1080.
54. Lackner TE, Cloyd JC, Thomas LW, et al. Antiepileptic drug use in nursing home residents: effect of age, gender, and comedication on patterns of use. Epilepsia 1998; 39(10): 1083–1087.
55. Lader M. Some adverse effects of antipsychotics: prevention and treatment. J Clin Psychiatry 1999; 60(Suppl. 12): S18–S21.
56. Landay RA, Gonzalez MA, Taylor JC. Effect of phenobarbital on theophylline disposition. J Allergy Clin Immunol 1978; 62(1): 27–29.
57. Laroudie C, Salazar DE, Cosson JP, et al. Carbamazepine–nefazodone interaction in healthy subjects. J Clin Psychopharmacol 2000; 20(1): 46–53.
58. Leinonen E, Lillsunde P, Laukkanen V, et al. Effects of carbamazepine on serum antidepressant concentrations in psychiatric patients. J Clin Psychopharmacol 1991; 11(5): 313–318.
59. Leonard RF, Knott PJ, Rankin GO, et al. Phenytoin–salicylate interaction. Clin Pharmacol Ther 1981; 29(1): 56–60.
60. Levine M, Sheppard I. Biphasic interaction of phenytoin with warfarin. Clin Pharm 1984; 3(2): 200–203.
61. Levy RH. Cytochrome P450 isozymes and antiepileptic drug interactions. Epilepsia 1995; 36(Suppl. 5): S8–S13.
62. Linnet K, Olesen OV. Free and glucuronidated olanzapine serum concentrations in psychiatric patients: influence of carbamazepine comedication. Ther Drug Monit 2002; 24(4): 512–517.
63. Linnoila M, Viukari M, Vaisanen K, et al. Effect of anticonvulsants on plasma haloperidol and thioridazine levels. Am J Psychiatry 1980; 137(7): 819–821.
64. Lucas RA, Gilfillan DJ, Bergstrom RF. A pharmacokinetic interaction between carbamazepine and olanzapine: observations on possible mechanism. Eur J Clin Pharmacol 1998; 54(8): 639–643.
65. Luo G, Cunningham M, Kim S, et al. CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab Dispos 2002; 30(7): 795–804.
66. Ma B, Prueksaritanont T, Lin JH. Drug interactions with calcium channel blockers: possible involvement of metabolite-intermediate complexation with CYP3A. Drug Metab Dispos 2000; 28(2): 125–130.
67. MacKichan J. Influence of protein binding and use of unbound (free) drug concentrations. In Applied Pharmacokinetics. W. Evans, J. Schentag, W. Jusko, eds. Vancouver, WA: Applied Therapeutics, Inc., 1992.
68. Macphee GJ, McInnes GT, Thompson GG, et al. Verapamil potentiates carbamazepine neurotoxicity: a clinically important inhibitory interaction. Lancet 1986; 1(8483): 700–703.
69. Martinez C, Albet C, Agundez JA, et al. Comparative in vitro and in vivo inhibition of cytochrome P450 CYP1A2, CYP2D6, and CYP3A by H2-receptor antagonists. Clin Pharmacol Ther 1999; 65(4): 369–376.
70. Massey EW. Effect of carbamazepine on Coumadin metabolism. Ann Neurol 1983; 13(6): 691–692.
71. Mattson RH, Cramer JA, Dorney PD, et al. Use of oral contraceptives by women with epilepsy. J Am Med Assoc 1986; 256(2): 238–240.
72. Mayersohn M. Special Pharmacokinetic Considerations in the Elderly. In Applied Pharmacokinetics. W. Evans, J. Schentag and W. Jusko, eds. Vancouver, WA: Applied Therapeutics, Inc., 1992.
73. Mazzu AL, Lasseter KC, Shamblen EC, et al. Itraconazole alters the pharmacokinetics of atorvastatin to a greater extent than either cerivastatin or pravastatin. Clin Pharmacol Ther 2000; 68(4): 391–400.
74. McElnay JC, Uprichard G, Collier PS. The effect of activated dimethicone and a proprietary antacid preparation containing this agent on the absorption of phenytoin. Br J Clin Pharmacol 1982; 13(4): 501–505.
75. Mendez JS, Cotzias GC, Mena I, et al. Diphenylhydantoin. Blocking of levodopa effects. Arch Neurol 1975; 32(1): 44–46.
76. Miceli JJ, Anziano RJ, Roberge L, et al. The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers. Br J Clin Pharmacol 2000; 49(Suppl. 1): S65–S70.
77. Michelucci R, Tassinari C. Benzodiazepines-adverse effects. In Antiepileptic Drugs. R. Levy, R. Mattson, B. Meldrun, E. Percucca, eds. Philadelphia, PA: Lippincott Williams & Wilkins, 2002.
78. Miller M, Cosgriff J, Kwong T, et al. Influence of phenytoin on theophylline clearance. Clin Pharmacol Ther 1984; 35(5): 666–669.
79. Miners JO, Attwood J, Birkett DJ. Determinants of acetaminophen metabolism: effect of inducers and inhibitors of drug metabolism on acetaminophen’s metabolic pathways. Clin Pharmacol Ther 1984; 35(4): 480–486.
80. Mula M, Monaco F. Carbamazepine–risperidone interactions in patients with epilepsy. Clin Neuropharmacol 2002; 25(2): 97–100.
81. Mungall DR, Ludden TM, Marshall J, et al. Population pharmacokinetics of racemic warfarin in adult patients. J Pharmacokinet Biopharm 1985; 13(3): 213–227.
82. Nappi JM. Warfarin and phenytoin interaction. Ann Intern Med 1979; 90(5): 852.
83. Nelson MH, Birnbaum AK, Remmel RP. Inhibition of phenytoin hydroxylation in human liver microsomes by several selective serotonin re-uptake inhibitors. Epilepsy Res 2001; 44(1): 71–82.
84. Neurontin (2002). Package Insert. Pfizer, Inc. Nitz N, Garrard J, Harms S, et al. Prevalence of antiepileptic drug use among medicare beneficiaries. Epilepsia 2000; 41(Suppl. 7): S251.
85. Nolan L, O’Malley K. Adverse drug reactions in the elderly. Br J Hosp Med 1989; 41(5): 446, 448, 452–457.
86. Oles KS, Mirza W, Penry JK. Catastrophic neurologic signs due to drug interaction: Tegretol and Darvon. Surg Neurol 1989; 32(2): 144–151.
87. Olesen OV, Linnet K. Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication. Ther Drug Monit 1999; 21(1): 87–90.
88. Ono S, Mihara K, Suzuki A, et al. Significant pharmacokinetic interaction between risperidone and carbamazepine: its relationship with CYP2D6 genotypes. Psychopharmacology (Berl) 2002; 162(1): 50–54.
89. Panegyres PK, Rischbieth RH. Fatal phenytoin warfarin interaction. Postgrad Med J 1991; 67(783): 98.
90. Paoletti R, Corsini A, Bellosta S. Pharmacological interactions of statins. Atheroscler Suppl 2002; 3(1): 35–40.
91. Pihlsgard M, Eliasson E. Significant reduction of sertraline plasma levels by carbamazepine and phenytoin. Eur J Clin Pharmacol 2002; 57(12): 915–916.
92. Prichard PJ, Walt RP, Kitchingman GK, et al. Oral phenytoin pharmacokinetics during omeprazole therapy. BrJ Clin Pharmacol 1987; 24(4): 543–545.
93. Ramsay RE, Slater JD. Effects of antiepileptic drugs on hormones. Epilepsia 1991; 32(Suppl. 6): S60–S67.
94. Ramsay R, Rowan A, Slater J, et al. Effect of age on epilepsy and its treatment: results of the VA cooperative study. Epilepsia 1994; 35(Suppl. 8): 91A.
95. Raucy JL, Mueller L, Duan K, et al. Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes. J Pharmacol Exp Ther 2002; 302(2): 475–482.
96. Reminyl (2003). Package Insert. Janssen Pharmaceutical Products. L. P., Titusville, NJ.
97. Rosenfeld WE, Doose DR, Walker JA, et al. Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy. Epilepsia 1997; 38(3): 317–323.
98. Ross JR, Beeley L. Interaction between carbamazepine and warfarin. Br Med J 1980; 280(6229): 1415–1416.
99. Rotzinger S, Baker GB. Human CYP3A4 and the metabolism of nefazodone and hydroxynefazodone by human liver microsomes and heterologously expressed enzymes. Eur Neuropsychopharmacol 2002; 12(2): 91–100.
100. Saano V, Glue P, Banfield CR, et al. Effects of felbamate on the pharmacokinetics of a low-dose combination oral contraceptive. Clin Pharmacol Ther 1995; 58(5): 523–531.
101. Schachter SC, Cramer GW, Thompson GD, et al. An evaluation of antiepileptic drug therapy in nursing facilities. J Am Geriatr Soc 1998; 46(9): 1137–1141.
102. Schmider J, Greenblatt DJ, Von Moltke LL, et al. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation. Br J Clin Pharmacol 1997; 44(5): 495–498.
103. Shaughnessy AF, Mosley MR. Elevated carbamazepine levels associated with diltiazem use. Neurology 1992; 42(4): 937–938.
104. Shin JG, Park JY, Kim MJ, et al. Inhibitory effects of tricyclic antidepressants (TCAs) on human cytochrome P450 enzymes in vitro: mechanism of drug interaction between TCAs and phenytoin. Drug Metab Dispos 2002; 30(10): 1102–1107.
105. Sitsen J, Maris F, Timmer C. Drug–drug interaction studies with mirtazapine and carbamazepine in healthy male subjects. Eur J Drug Metab Pharmacokinet 2001; 26(1–2): 109–121.
106. Sklar SJ, Wagner JC. Enhanced theophylline clearance secondary to phenytoin therapy. Drug Intell Clin Pharm 1985; 19(1): 34–36.
107. Spina E, Avenoso A, Pollicino AM, et al. Carbamazepine coadministration with fluoxetine or fluvoxamine. Ther Drug Monit 1993; 15(3): 247–250.
108. Stewart RB. Drug use in the elderly. In Therapeutics in the Elderly. J. Delafuente, R. Stewart, eds. Cincinnati: Harvey Whitney, 2001: 235–256.
109. Tang C, Shou M, Mei Q, et al. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J Pharmacol Exp Ther 2000; 293(2): 453–459.
110. Trileptal (2001). Package Insert. Novartis. Ucar M, Neuronen M, Luurila H, et al. Carbamazepine markedly reduces serum concentrations of simvastatin and simvastatin acid. Eur J Pharmacol 2004; 59: 879–882.
111. Udall JA. Clinical implications of warfarin interactions with five sedatives. Am J Cardiol 1975; 35(1): 67–71.
112. Ultram (2000). Package Insert. Ortho-McNeil Pharmaceutical, Inc. Wallace SM, Verbeeck RK. Plasma protein binding of drugs in the elderly. Clin Pharmacokinet 1987; 12(1): 41–72.
113. Wang RW, Kari PH, Lu AY, et al. Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 1991; 290(2): 355–361.
114. Webster LK, Mihaly GW, Jones DB, et al. Effect of cimetidine and ranitidine on carbamazepine and sodium valproate pharmacokinetics. Eur J Clin Pharmacol 1984; 27(3): 341–343.
115. Wellbutrin (1999). Package Insert. Glaxo Smith-Kline. Wen X, Wary JS, Bockman JT, et al. Genfibrozil is a potent inhibitor of human cytochrome P4502C9. Drug Metab Dispos 2001; 29: 1354–1361.
116. Wong YW, Yeh C, Thyrum PT. The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine. J Clin Psychopharmacol 2001; 21(1): 89–93.
117. Woods DJ, Coulter DM, Pillans P. Interaction of phenytoin and fluoxetine. NZ Med J 1994; 107(970): 19.
118. Yu YL, Huang CY, Chin D, et al. Interaction between carbamazepine and dextropropoxyphene. Postgrad Med J 1986; 62(725): 231–233.